This year was marked by various challenges, including war, natural disasters, and inflation, yet we managed to make significant strides in research. Our research report reflects the tireless dedication and innovative spirit of MLL's team as we continue to push the boundaries of knowledge in the field of hematology.

Our diagnostic workflows continued to evolve and expand, enabling us to provide now diagnostics for hemoglobinopathies and efficient and targeted diagnostic procedures for patients with unclear cytopenias. Additionally, our implementation of flow cytometry-based cell sorting has proven successful and a NovaSeq X series device was added to our sequencing facility, enabling faster and more cost-effective sequencing.

We also delve into the application of ML-based models in hematology diagnostics, providing valuable insights into the integration of AI algorithms to improve the accuracy, efficiency, and reproducibility of clinical diagnostics. This report also discusses the latest trends in hematology and also addresses the ongoing debate about the two classification guidelines for hematologic neoplasms and their potential implications for patients and physicians.

Our team has been fortunate enough to participate in various national and international research projects this year. By sharing our extensive knowledge of hematologic neoplasms, biobank and data collection with other research groups, we have been able to facilitate a range of fascinating research projects of which we highlight a few in more detail.

Enjoy the reading!